港股创新药继续井喷，T+0交易的港股通创新药ETF(159570)暴涨3%再创新高！

Core Viewpoint - The innovative pharmaceutical sector, particularly the Hong Kong Stock Connect innovative drug segment, is experiencing significant growth, with the index and major stocks showing strong upward trends [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug index (987018) has risen by 1.38%, with key stocks like Tigermed (03347) increasing over 7% and others like Kanglong Chemical (03759) and 3SBio rising over 5% [1]. - The Hong Kong Stock Connect innovative drug ETF (159570) has seen a 2.7% increase, with trading volume surpassing 700 million yuan, marking a historical high [1][3]. - Over the past five days, the Hong Kong Stock Connect innovative drug ETF has attracted a total net inflow of 736 million yuan, averaging 147 million yuan daily [3]. Group 2: Investment Trends - Leverage funds are increasingly being utilized, with the latest financing buy-in for the Hong Kong Stock Connect innovative drug ETF reaching 222 million yuan [3]. - The upcoming American Society of Clinical Oncology (ASCO) annual meeting is expected to showcase a growing number of Chinese pharmaceutical companies, with 73 studies selected for oral presentations in 2025 [3]. Group 3: Sector Analysis - Domestic innovative drugs are gaining competitive strength in the global market, with international investors showing increasing confidence in Chinese pharmaceutical companies [3]. - The Hong Kong Stock Connect innovative drug ETF (159570) has a significant focus on the innovative drug industry, with the top ten holdings accounting for nearly 72% of the total weight [4][5]. - The ETF is characterized by a high concentration in innovative drugs, with an 85% weight in this category, and is considered undervalued compared to historical sales ratios [5].